To read more about the latest highlights related to the PDC market, get a snapshot of the key highlights entailed in the ...

Under the agreement, Neomorph will receive an undisclosed upfront payment from AbbVie and be eligible for up to $1.64 billion in aggregate option fees and milestones.

We recently compiled a list of the 15 Best Large-Cap Value Stocks to Buy in 2025. In this article, we are going to take a ...

Guangzhou Fermion Technology Co., Ltd. and Simcere Pharmaceutical Group Limited (HKEX: 2096) have announced a partnership to develop a clinical-stage pain treatment asset, FZ002-037, targeting SSTR4.

Fermion and Simcere Pharma ink partnership to develop a clinical-stage pain treatment asset, FZ002-037, targeting SSTR4: Guangzhou, China Monday, January 20, 2025, 11:00 Hrs [IST] ...

Simcere Pharmaceutical Group Limited (2096.HK) is a pharmaceutical company driven by innovative R&D, and houses a "State Key Laboratory of Neurology and Oncology Drug Development".

GUANGZHOU, China, Jan. 18, 2025 /PRNewswire/ -- Guangzhou Fermion technology Co., Ltd. and Simcere Pharmaceutical Group Limited (HKEX: 2096) have announced a partnership to develop a clinical ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Earlier this week, AbbVie announced an option-to-license agreement with Simcere Zaiming for the development of an investigational drug candidate, SIM0500. Simcere Zaiming will gain an upfront payment ...